Study of AZD5305 When Given in Combination With New Hormonal Agents in Patients With Metastatic Prostate Cancer
← catalyst calendarNCT05367440 · readout in 1,696 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →. With Bayer.
Phase
Phase 1/2
Status
Active, not recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
174actual
Sites
20
Countries
Australia, Italy, United Kingdom +1
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2022-06-02 | actual | When the study began enrolling |
| Primary completion | 2031-04-11 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2031-04-11 | estimated | The whole study's end, after follow-up |
| First posted | 2022-05-10 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-01 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Metastatic Prostate Cancer
Interventions
- Drug: AZD5305
- Drug: Enzalutamide — also filed as Xtandi
- Drug: Abiraterone Acetate — also filed as Zytiga
- Drug: Darolutamide — also filed as Nubeqa
- Drug: Apalutamide — also filed as Erleada
Primary outcomes
what the primary-completion date above is the date OFNumber of patients with Adverse Events and Serious Adverse Events
measured Up to post treatment follow-up (28 days after last dose) [assessed up to 2.3 years]
Part A: Number of patients with Dose Limiting Toxicities (DLTs)
measured For Arm 1: 35 days, For Arm 2 and 3: 28 days
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed